Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Tivozanib
Synonyms
Therapy Description

Tivozanib (AV-951) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tivozanib Fotivda AV-951|AV951|KIL-8951|KRN 951|KRN-951 VEGFR Inhibitor (Pan) 32 Fotivda (tivozanib) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831, PMID: 31810797, PMID: 32547647). Fotivda(tivozanib) is FDA approved for use in adult patients with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown renal cell carcinoma not applicable Tivozanib FDA approved Actionable In a Phase III trial (TIVO-3) that supported FDA approval, Fotivda (tivozanib) was better tolerated than Nexavar (sorafenib), and improved progression-free survival (5.6 vs 3.9 months, HR=0.73, p=0.016) in patients with metastatic renal cell carcinoma that had at least two previous systemic treatments (PMID: 31810797; NCT02627963). detail... 31810797
Unknown unknown renal cell carcinoma not applicable Tivozanib Phase III Actionable In a Phase III trial, Fotivda (tivozanib) demonstrated improved progression free survival compared with Nexavar (sorafenib) as initial targeted therapy in patients with metastatic renal cell carcinoma (PMID: 24019545; NCT01030783). 24019545
NRAS mutant acute myeloid leukemia predicted - resistant Tivozanib Preclinical - Patient cell culture Actionable In a preclinical study, NRAS mutations correlated with resistance to Fotivda (tivozanib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627). 30333627
Unknown unknown Advanced Solid Tumor not applicable Tivozanib Phase I Actionable In a Phase I clinical study, Fotivda (tivozanib) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (Clin Cancer Res, November 15, 2011 17; 7156). detail...
Unknown unknown fibrosarcoma not applicable Tivozanib Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with Fotivda (tivozanib) resulted in partial inhibition of tumor growth and decreased tumor vasulature in a fibrosarcoma cell line xenograft model (PMID: 25995436). 25995436

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04645160 Phase Ib/II Tivozanib Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma Not yet recruiting USA 0
NCT01853644 Phase II Tivozanib Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT02627963 Phase III Sorafenib Tivozanib A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC Active, not recruiting USA | CAN 10
NCT01835223 Phase Ib/II Tivozanib Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT01972516 Phase II Tivozanib Tivozanib As Maintenance Therapy In GYN Terminated USA 0


Additional content available in CKB BOOST